Skip to main content
drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic)
drug_description
Anti-HER2 IgG monoclonal antibody (binds domain II) that prevents HER2 dimerization and induces ADCC.
nci_thesaurus_concept_id
C38692
nci_thesaurus_preferred_term
Pertuzumab
nci_thesaurus_definition
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)
drug_mesh_term
Pertuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti‑HER2 IgG1 monoclonal antibody that binds HER2 extracellular domain II, blocking HER2 homo/heterodimerization and downstream PI3K/AKT/MAPK signaling, and engaging Fcγ receptors to mediate antibody‑dependent cellular cytotoxicity (ADCC), leading to tumor cell growth inhibition and apoptosis.
drug_name
Pertuzumab
nct_id_drug_ref
NCT05838066